文献速递心脏核医学肿瘤 PET/CT

系列定量评估18F-氟脱氧葡萄糖PET/CT摄取对伴室性心动过速的心脏结节病患者预后的作用

Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-04-02

本研究随访20例接受导管消融的伴室性心动过速的心脏结节病患者,共92次系列FDG-PET扫描,定量分析病灶代谢活性变化。中位随访35个月,12例(60%)发生18次主要不良心脏事件;

要点

  • 伴室性心动过速的心脏结节病患者中,缺乏PET改善(LMA下降不足25%)与随访期MACE风险升高相关(HR 18.96)。
  • LMA变化与左心室射血分数变化呈显著线性负相关(β=-20.11,p=0.003)。
  • FDG摄取随时间的变化与收缩功能平行变化相关,FDG摄取降低与长期随访MACE减少强相关。

核心结论

  • 在伴室性心动过速的心脏结节病患者中,定量评估的FDG摄取随时间变化与收缩功能平行变化相关,FDG摄取降低与长期随访MACE减少强相关。

研究设计与样本

  • 随访20例(51±9岁,70%男性)伴室性心动过速并接受导管消融的心脏结节病患者,共进行92次系列FDG-PET扫描(每人3-10次)。
  • 采用SUVmax、部分容积校正的SUVmean和部分容积校正的容积-强度乘积(LMA)定量心肌FDG高摄取病灶,并计算全心脏容积-强度乘积(gCMA)和背景心脏代谢活性(bCMA,即gCMA与LMA之差)。
  • 主要终点为主要不良心脏事件(MACE),包括死亡、心脏移植、心力衰竭住院和植入式心律转复除颤器(ICD)适当干预;同时评估随访期超声心动图参数演变。

主要发现

  • 中位随访35(20-66)个月,12例(60%)患者发生18次MACE(1例死亡、2例心脏移植、12次ICD适当干预、3次住院)。
  • 单变量分析中,缺乏PET改善(定义为LMA下降至少25%)是随访期唯一与心脏事件相关的变量。
  • LMA变化与左心室射血分数变化呈显著线性负相关(β=-20.11;p=0.003)。

关键数值与推荐

  • PET改善定义为LMA下降至少25%。
  • 无应答者MACE风险HR 18.96(95%CI 2.26-159.27;p=0.007)。
  • LMA变化与左心室射血分数变化的线性回归β=-20.11(p=0.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) has shown to be useful in diagnosis, staging and monitoring of cardiac sarcoidosis (CS) but its interpretation is not standardized. OBJECTIVES: We sought to investigate the clinical impact of serial quantitative FDG uptake analysis in patients with CS presenting with ventricular tachycardia (VT) treated by catheter ablation (CA). METHODS: We followed 20 patients (51 ± 9 years, 70% males) with CS and VT who underwent CA, with 92 serial FDG-PET scans (3-10 per patient). Myocardial FDG-avid lesions were quantified using three parameters: maximum standardized uptake value (SUVmax), partial-volume corrected mean standardized uptake value (SUVmean) and partial-volume corrected volume-intensity product [lesion metabolic activity (LMA)]. The volume-intensity product of the entire heart [global cardiac metabolic activity (gCMA)] and the background cardiac metabolic activity (bCMA: difference between gCMA and LMA) were also calculated. The primary end-point was the occurrence of major adverse cardiac events (MACE), including death, heart transplant, hospitalization for heart failure and implantable cardioverter defibrillator (ICD) appropriate interventions. Evolution of echocardiographic parameters over follow-up was also assessed. RESULTS: During a median follow-up of 35 (20-66) months, 18 MACE (1 death, 2 heart transplants, 12 ICD appropriate interventions, 3 hospitalizations) occurred in 12 (60%) patients. At univariable analysis, lack of PET improvement (defined by decrease in LMA of at least 25%) was the only variable associated with cardiac events during follow-up. In particular, non-responders had a 20-fold higher risk of MACE at follow-up (HR 18.96, 95% CI 2.26-159.27; p = 0.007). Moreover, a significant linear inverse relationship was observed between changes in LMA and changes in left ventricular ejection fraction over follow-up (β = -20.11; p = 0.003). CONCLUSIONS: In patients with CS and VT, temporal change in FDG uptake evaluated by a quantitative approach is associated with parallel change in systolic function. Moreover, reduction in FDG uptake is strongly associated with fewer MACE at long-term follow-up.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Muser D, Santangeli P, Castro SA, et al. Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia. Eur J Nucl Med Mol Imaging. 2018. PMID: 29610956. doi:10.1007/s00259-018-4001-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。